<DOC>
	<DOCNO>NCT01958827</DOCNO>
	<brief_summary>The purpose study investigate efficacy , safety pharmacokinetics dose escalation Japanese subject Crohn 's Disease .</brief_summary>
	<brief_title>A Study Adalimumab After Dose Escalation Japanese Subjects With Crohn 's Disease</brief_title>
	<detailed_description>Subjects confirm meet inclusion criterion none exclusion criterion screen period ( ≤ 21 day ) give subcutaneous injection open-label adalimumab 80 mg eow Week 0 Week 50 . If subject inadequate response Week 8 , subject may withdraw study . Self-injection study drug permit subject willing perform self-injection , investigator decide appropriate . Disease activity evaluate Crohn 's disease activity index ( CDAI ) Screening , Week 0 every 4 week Week 52 . Follow-up perform 70 day last dose study drug visit telephone .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject ≥ 15 year age time informed consent . Subject Crohn 's disease receive induction treatment commercially available Humira® ( 160 mg initially 80 mg 2 week initial dose ) , achieve response initial dose , lose response maintenance treatment Humira® . Subject elevate Creactive Protein ( CRP ) Screening . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy and/or hysterectomy ) childbearing potential practicing approve method birth control throughout study 150 day last dose study drug . Subject negative tuberculosis ( TB ) screen assessment . If subject evidence latent TB infection ; subject must initiate complete minimum 21 day ongoing TB prophylaxis ( case , screen period prolong 21 day past initiation prophylaxis study drug administer ) document completion full course TB prophylaxis , prior Week 0 . Subject suspicion colitis Crohn 's disease . Subject ostomy ileoanal pouch . ( Subjects previous ileorectal anastomosis exclude ) . Subject abscess suspicion abscess , subject infection ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Dose Escalation</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>